SillaJen Registers Korean Patent for Neutralizing Antibody Evasion Characteristic of 'SJ-607'

Official Recognition of Neutralizing Antibody Evasion Mechanism
First-ever Securing of Rights for Repeated Intravenous Administration

On September 30, SillaJen announced that the neutralizing antibody evasion function of its next-generation oncolytic virus platform, SJ-607, has been successfully registered as a patent in Korea.

With this patent registration, SillaJen has secured the exclusive rights for the first time to repeated intravenous administration and therapeutic uses based on the neutralizing antibody evasion characteristic.

SJ-607 is the foundational oncolytic virus platform of the SJ-600 series and represents an original asset developed independently by researchers at the SillaJen Research Center through their own research and development (R&D).

SJ-607 is a technology that induces the expression of CD55 on the viral envelope, enabling it to avoid not only complement-mediated neutralization but also neutralization by antibodies, thereby making repeated intravenous administration possible.

In contrast, traditional oncolytic viruses are rapidly eliminated by complement and neutralizing antibodies when administered intravenously; in particular, repeated dosing leads to an increase in neutralizing antibodies, which decreases anti-cancer efficacy.

The research team is focusing on overcoming the shortcomings of existing oncolytic viruses and is developing a platform technology that can be loaded with additional anticancer agents, aiming to enhance both anti-cancer effects and the scalability of the technology.

Currently, the SJ-600 series is undergoing process development and preparation for toxicity studies at Reithera, a global contract development and manufacturing organization (CDMO) based in Italy.

A SillaJen spokesperson stated, "With this patent registration, the therapeutic application allowing repeated intravenous dosing is now protected as an intellectual property, which will be a significant benefit for future commercialization and business development."

This content was produced with the assistance of AI translation services.